Literature DB >> 7215416

Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.

K Landmark, J E Bredesen, E Thaulow, S Simonsen, J P Amlie.   

Abstract

The parmacokinetics of disopyramide (DP) in 10 patients with imminent to moderate cardiac failure has been studied and compared with the results in normal volunteers. The biological half life of rapid distribution (T1/2 alpha) and of elimination (T1/2 beta) were increased (11.1 +/- 4.4 min and 9.7 +/- 4.2 h, respectively). Total body clearance (Clt) was decreased (0.467 +/- 0.215 ml . min-1 . kg-1), and the volume of distribution (Vd) was slightly reduced (0.610 +/- 0.1361 . kg-1), probably due to the lower cardiac index. After oral administration, the time of peak serum concentration was increased (139 +/- 89 min), and the mean peak serum concentration (2.4 +/- 0.8% dose . 1-1) was also higher than reported in normal subjects. Comparison of the areas under the concentration versus time curves after intravenous and oral administration (AUC i. v. and AUC oral) showed that DP was almost completely absorbed, its bioavailability being 97.5 +/- 15.0%.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7215416     DOI: 10.1007/bf00561947

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  The effect of congestive heart failure on quinidine pharmacokinetics.

Authors:  W G Crouthamel
Journal:  Am Heart J       Date:  1975-09       Impact factor: 4.749

3.  Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.

Authors:  R E Rangno; W Warnica; R I Ogilvie; J Kreeft; E Bridger
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

4.  Acute termination of cardiac arrhythmias with intravenous disopyramide.

Authors:  H F Mizgala; P R Huvelle
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

5.  The use of disopyramide in the treatment of arrhythmias in ambulatory patients.

Authors:  M B Jones
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

6.  Effects of disopyramide on electrophysiologic properties of canine cardiac purkinje fibers.

Authors:  P Danilo; A J Hordof; M R Rosen
Journal:  J Pharmacol Exp Ther       Date:  1977-06       Impact factor: 4.030

7.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

8.  Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency.

Authors:  S Bellet; L R Roman; A Boza
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

9.  Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.

Authors:  J Hulting; G Rosenhamer
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

10.  Disopyramide plasma levels in cardiac patients on maintenance therapy.

Authors:  K Landmark; L Storstein; A Larsen
Journal:  Acta Med Scand       Date:  1979
View more
  11 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

Review 4.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Disopyramide pharmacokinetics during recovery from myocardial infarction.

Authors:  S M Bryson; C J Cairns; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 7.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

8.  Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.

Authors:  E Lien; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

9.  Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.

Authors:  J J Lima; D B Haughey; C V Leier
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

10.  Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.

Authors:  B M David; K F Ilett; E G Whitford; N S Stenhouse
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.